BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, Tapete G, Costa F. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol 2018; 24(33): 3681-3694 [PMID: 30197475 DOI: 10.3748/wjg.v24.i33.3681] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 98] [Article Influence: 24.3] [Reference Citation Analysis]
Number Citing Articles
1 Silva I, Estarreja J, Pinto R, Mateus V. Efficacy and safety of erythropoietin in a chronic model of Inflammatory Bowel Disease. Biomedicine & Pharmacotherapy 2022;156:113944. [DOI: 10.1016/j.biopha.2022.113944] [Reference Citation Analysis]
2 Zhu M, Fan L, Han M, Zhu S, Zhang S, Shi H. The usefulness of fecal hemoglobin and calprotectin tests in diagnosing significant bowel diseases: a prospective study. Scand J Gastroenterol 2022;:1-7. [PMID: 36260495 DOI: 10.1080/00365521.2022.2133551] [Reference Citation Analysis]
3 Xiao Q, Yu F, Yan L, Zhao H, Zhang F. Alterations in circulating markers in HIV/AIDS patients with poor immune reconstitution: Novel insights from microbial translocation and innate immunity. Front Immunol 2022;13:1026070. [DOI: 10.3389/fimmu.2022.1026070] [Reference Citation Analysis]
4 Domislovic V, Høg Mortensen J, Lindholm M, Kaarsdal MA, Brinar M, Barisic A, Manon-jensen T, Krznaric Z. Inflammatory Biomarkers of Extracellular Matrix Remodeling and Disease Activity in Crohn’s Disease and Ulcerative Colitis. JCM 2022;11:5907. [DOI: 10.3390/jcm11195907] [Reference Citation Analysis]
5 Facciorusso A, Ramai D, Ricciardelli C, Paolillo R, Maida M, Chandan S, Mohan BP, Domislovic V, Sacco R. Prognostic Role of Post-Induction Fecal Calprotectin Levels in Patients with Inflammatory Bowel Disease Treated with Biological Therapies. Biomedicines 2022;10:2305. [DOI: 10.3390/biomedicines10092305] [Reference Citation Analysis]
6 Roshidi N, Arifin N, Gonzalez Salazar F. Disease Biomarkers of Giardiasis. Journal of Parasitology Research 2022;2022:1-12. [DOI: 10.1155/2022/1932518] [Reference Citation Analysis]
7 Milde AM, Rød AMK, Brekke S, Gjøen H, Mesfin G, Murison R. Does a single exposure to social defeat render rats more vulnerable to chemically induced colitis than brief inescapable foot-shocks? PLoS ONE 2022;17:e0263802. [DOI: 10.1371/journal.pone.0263802] [Reference Citation Analysis]
8 Silva I, Correia R, Pinto R, Mateus V. Hemin Ameliorates the Inflammatory Activity in the Inflammatory Bowel Disease: A Non-Clinical Study in Rodents. Biomedicines 2022;10:2025. [DOI: 10.3390/biomedicines10082025] [Reference Citation Analysis]
9 Silva I, Mendes P, Guerra S, Pinto R, Mateus V. Anti-Inflammatory Effect of Topiramate in a Chronic Model of TNBS-Induced Colitis. IJMS 2022;23:9127. [DOI: 10.3390/ijms23169127] [Reference Citation Analysis]
10 Campos JF, Resende GG, Barbosa AJA, de Carvalho SC, Lage JA, Cunha PFS, de Souza SCS, Ferrari MLA. Fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis. Int J Rheum Dis 2022. [PMID: 35855677 DOI: 10.1111/1756-185X.14388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Grgić D, Golubić K, Brinar M, Krznarić Ž. Predictive value of faecal calprotectin in ulcerative colitis - single centre experience. Ann Med 2022;54:1570-7. [PMID: 35635011 DOI: 10.1080/07853890.2022.2082518] [Reference Citation Analysis]
12 Watermeyer G, Awuku Y, Fredericks E, Epstein D, Setshedi M, Devani S, Mudombi W, Kassianides C, Katsidzira L. Challenges in the management of inflammatory bowel disease in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00048-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bertani L, Barberio B, Fornili M, Antonioli L, Zanzi F, Casadei C, Benvenuti L, Facchin S, D'antongiovanni V, Lorenzon G, Ceccarelli L, Baglietto L, de Bortoli N, Bellini M, Costa F, Savarino EV, Fornai M. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Barberio B, Facchin S, Patuzzi I, Ford AC, Massimi D, Valle G, Sattin E, Simionati B, Bertazzo E, Zingone F, Savarino EV. A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach. Gut Microbes 2022;14:2028366. [DOI: 10.1080/19490976.2022.2028366] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Pakoz ZB, Ustaoglu M, Vatansever S, Yuksel ES, Topal F, Adani GL. Serum Immune-Inflammation Index Assessment in the Patients with Ulcerative Colitis. Gastroenterology Research and Practice 2022;2022:1-5. [DOI: 10.1155/2022/9987214] [Reference Citation Analysis]
16 Milde AM, Rød AMK, Brekke S, Gjøen H, Mesfin G, Murison R. Does a single exposure to social defeat render rats more vulnerable to chemically induced colitis than brief inescapable foot-shocks?. [DOI: 10.1101/2022.01.28.478146] [Reference Citation Analysis]
17 de Almeida LG, Dufour A. Proteases are cut out to regulate acute and chronic inflammation. Proteolytic Signaling in Health and Disease 2022. [DOI: 10.1016/b978-0-323-85696-6.00003-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Trasolini R, Zhu K, Klemm N, Park S, Salh B. Fecal Leukocyte Esterase, an Alternative Biomarker to Fecal Calprotectin in Inflammatory Bowel Disease: A Pilot Series. Gastro Hep Advances 2022;1:45-51. [DOI: 10.1016/j.gastha.2021.10.006] [Reference Citation Analysis]
19 Park SY, Lee SP, Kim WJ. Fecal Calprotectin Is Increased in Stroke. JCM 2021;11:159. [DOI: 10.3390/jcm11010159] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Kumric M, Zivkovic PM, Ticinovic Kurir T, Vrdoljak J, Vilovic M, Martinovic D, Bratanic A, Lizatovic IK, Bozic J. Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease. Diagnostics 2022;12:45. [DOI: 10.3390/diagnostics12010045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Christensen KR, Steenholdt C, Buhl S, Brynskov J, Ainsworth MA. A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence. Scand J Gastroenterol 2021;:1-8. [PMID: 34779308 DOI: 10.1080/00365521.2021.2002397] [Reference Citation Analysis]
23 Daoud ND, Hashash JG, Picco MF, Farraye FA. Fecal Calprotectin from Ileostomy Output is Sensitive and Specific for the Prediction of Small Bowel Inflammation in Patients with Crohn's Disease. J Crohns Colitis 2021:jjab182. [PMID: 34633435 DOI: 10.1093/ecco-jcc/jjab182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Corsi F, Sorrentino L, Albasini S, Colombo F, Cigognini M, Massari A, Morasso C, Mazzucchelli S, Piccotti F, Ardizzone S, Sampietro GM, Truffi M. Circulating Fibroblast Activation Protein as Potential Biomarker in Patients With Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:725726. [PMID: 34621763 DOI: 10.3389/fmed.2021.725726] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Moorman EL, Farrell M, Santucci N, Denson L, Le C, Cunningham NR. Elevated fecal calprotectin is linked to psychosocial complexity in pediatric functional abdominal pain disorders. BMC Res Notes 2021;14:360. [PMID: 34526124 DOI: 10.1186/s13104-021-05776-5] [Reference Citation Analysis]
26 Kostoff RN, Briggs MB, Kanduc D, Shores DR, Kovatsi L, Vardavas AI, Porter AL. Common contributing factors to COVID-19 and inflammatory bowel disease. Toxicol Rep 2021;8:1616-37. [PMID: 34485092 DOI: 10.1016/j.toxrep.2021.08.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Morasso C, Truffi M, Vanna R, Albasini S, Mazzucchelli S, Colombo F, Sorrentino L, Sampietro G, Ardizzone S, Corsi F. Raman Analysis Reveals Biochemical Differences in Plasma of Crohn's Disease Patients. J Crohns Colitis 2020;14:1572-80. [PMID: 32343792 DOI: 10.1093/ecco-jcc/jjaa080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
28 Yong HM, Park SJ, Jeon SR, Park H, Kim HG, Lee TH, Park J, Kim JO, Lee JS, Ko BM, Goong HJ, Park S. Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis. Medicine (Baltimore) 2021;100:e27065. [PMID: 34449501 DOI: 10.1097/MD.0000000000027065] [Reference Citation Analysis]
29 Chen F, Hu Y, Fan YH, Lv B. Clinical Value of Fecal Calprotectin in Predicting Mucosal Healing in Patients With Ulcerative Colitis. Front Med (Lausanne) 2021;8:679264. [PMID: 34414201 DOI: 10.3389/fmed.2021.679264] [Reference Citation Analysis]
30 Matson J, Ramamoorthy S, Lopez NE. The Role of Biomarkers in Surgery for Ulcerative Colitis: A Review. J Clin Med 2021;10:3362. [PMID: 34362144 DOI: 10.3390/jcm10153362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
31 Bertani L, Mumolo MG, Tapete G, Albano E, Baiano Svizzero G, Zanzi F, Ceccarelli L, Bellini M, Marchi S, Costa F. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. Eur J Gastroenterol Hepatol 2020;32:1091-8. [PMID: 32282400 DOI: 10.1097/MEG.0000000000001731] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 19.0] [Reference Citation Analysis]
32 Duan L, Cheng S, Li L, Liu Y, Wang D, Liu G. Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease. Front Pharmacol 2021;12:684486. [PMID: 34335253 DOI: 10.3389/fphar.2021.684486] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
33 Nardone OM, Shivaji UN, Ferruzza V, Ghosh S, Iacucci M. Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. Inflamm Bowel Dis 2020;26:961-9. [PMID: 31587036 DOI: 10.1093/ibd/izz226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
34 Campbell JP, Zierold C, Rode AM, Blocki FA, Vaughn BP. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome. J Clin Gastroenterol 2021;55:239-43. [PMID: 32324678 DOI: 10.1097/MCG.0000000000001359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
35 Bertani L, Blandizzi C, Mumolo MG, Ceccarelli L, Albano E, Tapete G, Baiano Svizzero G, Zanzi F, Coppini F, de Bortoli N, Bellini M, Morganti R, Marchi S, Costa F. Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. Clin Transl Gastroenterol 2020;11:e00174. [PMID: 32677804 DOI: 10.14309/ctg.0000000000000174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
36 D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, Olivera PA, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, Danese S, Peyrin-Biroulet L. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J 2021;9:451-60. [PMID: 33961734 DOI: 10.1002/ueg2.12069] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
37 State M, Negreanu L, Voiosu T, Voiosu A, Balanescu P, Mateescu RB. Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review. World J Gastroenterol 2021; 27(16): 1828-1840 [PMID: 33967560 DOI: 10.3748/wjg.v27.i16.1828] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Cui G, Fan Q, Li Z, Goll R, Florholmen J. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. EBioMedicine 2021;66:103329. [PMID: 33862588 DOI: 10.1016/j.ebiom.2021.103329] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
39 Suarez-Carantoña C, Rodriguez-Torres A, Viteri-Noel A, Pintado V, Garcia-Fernandez S, Mora-Pimentel D, Escudero-Sanchez R, Martin-Jusdado F, Moreno S, Cobo J. Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic Clostridioides difficile. J Clin Med 2021;10:1627. [PMID: 33921309 DOI: 10.3390/jcm10081627] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Capecchi R, Migliorini P, Zanzi F, Maltinti S, Puxeddu I, de Bortoli N, Bellini M, Costa F, Marchi S, Bertani L. Ig Glycosylation in Ulcerative Colitis: It's Time for New Biomarkers. Front Pharmacol 2021;12:654319. [PMID: 33897440 DOI: 10.3389/fphar.2021.654319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Bendix M, Dige A, Jørgensen SP, Dahlerup JF, Bibby BM, Deleuran B, Agnholt J. Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn's Disease during One-Year Follow-Up. Nutrients 2021;13:1083. [PMID: 33810258 DOI: 10.3390/nu13041083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
42 Sarrabayrouse G, Elias A, Yáñez F, Mayorga L, Varela E, Bartoli C, Casellas F, Borruel N, Herrera de Guise C, Machiels K, Vermeire S, Manichanh C. Fungal and Bacterial Loads: Noninvasive Inflammatory Bowel Disease Biomarkers for the Clinical Setting. mSystems 2021;6:e01277-20. [PMID: 33758031 DOI: 10.1128/mSystems.01277-20] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
43 Mylemans M, Nevejan L, Van Den Bremt S, Stubbe M, Cruyssen BV, Moulakakis C, Berthold H, Konrad C, Bossuyt X, Van Hoovels L. Circulating calprotectin as biomarker in neutrophil-related inflammation: Pre-analytical recommendations and reference values according to sample type. Clin Chim Acta 2021;517:149-55. [PMID: 33689693 DOI: 10.1016/j.cca.2021.02.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
44 Mizoguchi E, Subramaniam R, Okada T, Mizoguchi A. A Review of Selected IBD Biomarkers: From Animal Models to Bedside. Diagnostics (Basel) 2021;11:207. [PMID: 33573291 DOI: 10.3390/diagnostics11020207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
45 Naqvi SA, Taylor LM, Panaccione R, Ghosh S, Barkema HW, Hotte N, Shommu N, Kaur S, Reimer RA, Madsen KL, Raman M. Dietary patterns, food groups and nutrients in Crohn's disease: associations with gut and systemic inflammation. Sci Rep 2021;11:1674. [PMID: 33462267 DOI: 10.1038/s41598-020-80924-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
46 Sjöström B, Bredberg A, Mandl T, Alonso-Magdalena L, Ohlsson B, Lavasani S, Nouri M, Henriksson G. Increased intestinal permeability in primary Sjögren's syndrome and multiple sclerosis. J Transl Autoimmun 2021;4:100082. [PMID: 33506194 DOI: 10.1016/j.jtauto.2021.100082] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Wang W, Wu L, Wu X, Li K, Li T, Xu B, Liu W. Combined analysis of serum SAP and PRSS2 for the differential diagnosis of CD and UC. Clin Chim Acta 2021;514:8-14. [PMID: 33333044 DOI: 10.1016/j.cca.2020.12.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Varkey J. Graft assessment for acute rejection after intestinal transplantation: current status and future perspective. Scand J Gastroenterol 2021;56:13-9. [PMID: 33202155 DOI: 10.1080/00365521.2020.1847318] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Makhov VM, Romasenko LV, Panferov AS, Doroninа YA, Isaykina MA, Yurazh MV. Clinical and psychiatric comparison of diverticular disease of the colon and irritable bowel syndrome. jour 2020. [DOI: 10.31146/1682-8658-ecg-182-10-71-77] [Reference Citation Analysis]
50 Lężyk-Ciemniak E, Tworkiewicz M, Wilczyńska D, Szaflarska-Popławska A, Krogulska A. Usefulness of Testing for Fecal Calprotectin in Pediatric Gastroenterology Clinical Practice. Med Princ Pract 2021;30:311-9. [PMID: 33120396 DOI: 10.1159/000512631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Ruiz-Briseño MDR, De Arcos-Jiménez JC, Ratkovich-González S, Sánchez-Reyes K, González-Hernández LA, Andrade-Villanueva JF, Alvarez-Zavala M. Association of intestinal and systemic inflammatory biomarkers with immune reconstitution in HIV+ patients on ART. J Inflamm (Lond) 2020;17:32. [PMID: 33071649 DOI: 10.1186/s12950-020-00262-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
52 Kousgaard SJ, Michaelsen TY, Nielsen HL, Kirk KF, Albertsen M, Thorlacius-Ussing O. The Microbiota Profile in Inflamed and Non-Inflamed Ileal Pouch-Anal Anastomosis. Microorganisms 2020;8:E1611. [PMID: 33092101 DOI: 10.3390/microorganisms8101611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Acri G, Venuti V, Costa S, Testagrossa B, Pellegrino S, Crupi V, Majolino D. Raman Spectroscopy as Noninvasive Method of Diagnosis of Pediatric Onset Inflammatory Bowel Disease. Applied Sciences 2020;10:6974. [DOI: 10.3390/app10196974] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
54 Park SY. Age-Related Fecal Calprotectin Concentrations in Healthy Adults. Korean J Clin Lab Sci 2020;52:181-187. [DOI: 10.15324/kjcls.2020.52.3.181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Safwat E, Salah M, Hussein H. Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study. Arab J Gastroenterol 2020;21:273-7. [PMID: 32928705 DOI: 10.1016/j.ajg.2020.08.003] [Reference Citation Analysis]
56 Ramió‐pujol S, Amoedo J, Serra‐pagès M, Torrealba L, Bahí A, Serrano M, Malagón M, Ibáñez‐sanz G, Gilabert P, Marin I, Torres P, Cañete F, Mañosa M, Clos A, Miquel‐cusachs JO, Busquets D, Sàbat M, Serra J, Moss AC, Domènech E, Guardiola J, Mearín F, Santos J, Jesús Garcia‐gil L, Aldeguer X. A novel distinctive form of identification for differential diagnosis of irritable bowel syndrome, inflammatory bowel disease, and healthy controls. GastroHep 2020;2:193-204. [DOI: 10.1002/ygh2.417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Hanafy AS, Mohamed MS, Alnagar AA. Ascitic Calprotectin as an early predictor of hepatocellular carcinoma in patients with cirrhotic ascites. J Cancer Res Clin Oncol 2020;146:3207-14. [PMID: 32851478 DOI: 10.1007/s00432-020-03363-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Mckechnie T, Lee Y, Kruse C, Ramji K, Springer JE, Wood T, Doumouras AG, Hong D, Eskicioglu C. The role of fecal calprotectin in the diagnosis of acute pouchitis following IPAA for ulcerative colitis: a systematic clinical review. Int J Colorectal Dis 2020;35:1619-28. [DOI: 10.1007/s00384-020-03669-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
59 Armuzzi A, Bouhnik Y, Cummings F, Bettey M, Pieper B, Kang T. Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. Dig Liver Dis 2020;52:1259-65. [PMID: 32601035 DOI: 10.1016/j.dld.2020.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
60 Premjeyanth V, Shipman AR, Shipman KE. Faecal calprotectin in dermatology practice. Clin Exp Dermatol 2020;45:831-5. [DOI: 10.1111/ced.14307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
61 Sinniger V, Pellissier S, Fauvelle F, Trocmé C, Hoffmann D, Vercueil L, Cracowski J, David O, Bonaz B. A 12‐month pilot study outcomes of vagus nerve stimulation in Crohn's disease. Neurogastroenterology & Motility 2020;32. [DOI: 10.1111/nmo.13911] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 19.0] [Reference Citation Analysis]
62 Bertani L, Fornai M, Fornili M, Antonioli L, Benvenuti L, Tapete G, Baiano Svizzero G, Ceccarelli L, Mumolo MG, Baglietto L, de Bortoli N, Bellini M, Marchi S, Costa F, Blandizzi C. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther 2020;52:284-91. [PMID: 32506635 DOI: 10.1111/apt.15870] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
63 Sánchez-Hernández JG, Pérez-Blanco JS, Rebollo N, Muñoz F, Prieto V, Calvo MV. Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease. Eur J Pharm Sci 2020;150:105369. [PMID: 32416256 DOI: 10.1016/j.ejps.2020.105369] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
64 D'Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. J Crohns Colitis 2021;15:152-61. [PMID: 32392336 DOI: 10.1093/ecco-jcc/jjaa093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
65 Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med 2020;9:E1323. [PMID: 32370274 DOI: 10.3390/jcm9051323] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
66 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 23.0] [Reference Citation Analysis]
67 Yamamoto-Furusho JK, Mendieta-Escalante EA. Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis. PLoS One 2020;15:e0231988. [PMID: 32315368 DOI: 10.1371/journal.pone.0231988] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
68 Dihm K, Ek M, Roth B, Ohlsson B. Plasma AXIN1 expression exhibit negative correlations with inflammatory biomarkers and is associated with gastrointestinal symptoms in endometriosis. Biomed Rep 2020;12:211-21. [PMID: 32257184 DOI: 10.3892/br.2020.1282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
69 Bertani L, Rossari F, Barberio B, Demarzo MG, Tapete G, Albano E, Baiano Svizzero G, Ceccarelli L, Mumolo MG, Brombin C, de Bortoli N, Bellini M, Marchi S, Bodini G, Savarino E, Costa F. Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. Inflamm Bowel Dis. 2020;26:1579-1587. [PMID: 32232392 DOI: 10.1093/ibd/izaa062] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
70 Rottenstreich A, Mishael T, Granovsky SG, Koslowsky B, Schweistein H, Abitbol G, Goldin E, Shitrit AB. Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases. Eur J Intern Med 2020;77:105-10. [PMID: 32197833 DOI: 10.1016/j.ejim.2020.03.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Bertani L, Baglietto L, Antonioli L, Fornai M, Tapete G, Albano E, Ceccarelli L, Mumolo MG, Pellegrini C, Lucenteforte E, de Bortoli N, Bellini M, Marchi S, Blandizzi C, Costa F. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol 2020;86:1296-305. [PMID: 32027388 DOI: 10.1111/bcp.14235] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
72 Puig L. The safety of ixekizumab in psoriasis drug therapy. Expert Opinion on Drug Safety 2020;19:117-30. [DOI: 10.1080/14740338.2020.1709440] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
73 Goran L, State M, Negreanu AM, Negreanu L. Pursuing therapeutic success in Crohn’s disease: A matter of definition, tools and longterm outcomes. Eur J Inflamm 2020;18:205873922096289. [DOI: 10.1177/2058739220962896] [Reference Citation Analysis]
74 Tokmak S, Harmanci Özakyol A. Elevated Levels of Fecal Calprotectin in Cirrhotic Patients and Spontaneous Bacterial Peritonitis. Düzce Tıp Fakültesi Dergisi 2019. [DOI: 10.18678/dtfd.653549] [Reference Citation Analysis]
75 Schoepfer A, Vavricka SR, Brüngger B, Blozik E, Bähler C. Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland. Eur J Gastroenterol Hepatol 2020;32:350-7. [PMID: 31834046 DOI: 10.1097/MEG.0000000000001616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Bertani L, Bodini G, Mumolo MG, de Bortoli N, Ceccarelli L, Frazzoni L, Tapete G, Albano E, Plaz Torres MC, Bellini M, Savarino E, Savarino V, Marchi S, Costa F. Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. Dig Dis Sci 2020;65:2397-402. [DOI: 10.1007/s10620-019-05959-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
77 Abedin N, Seemann T, Kleinfeld S, Ruehrup J, Röseler S, Trautwein C, Streetz K, Sellge G. Fecal Eosinophil Cationic Protein Is a Diagnostic and Predictive Biomarker in Young Adults with Inflammatory Bowel Disease. J Clin Med 2019;8:E2025. [PMID: 31756948 DOI: 10.3390/jcm8122025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
78 Petryszyn P, Staniak A, Wolosianska A, Ekk-cierniakowski P. Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis. European Journal of Gastroenterology & Hepatology 2019;31:1306-12. [DOI: 10.1097/meg.0000000000001509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
79 Bathe AL, Mavropoulou E, Mechie NC, Petzold G, Ellenrieder V, Kunsch S, Amanzada A. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis. PLoS One 2019;14:e0223893. [PMID: 31647834 DOI: 10.1371/journal.pone.0223893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
80 Bertani L, Antonioli L, Fornai M, Tapete G, Baiano Svizzero G, Marchi S, Blandizzi C, Costa F. Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. Minerva Gastroenterol Dietol 2019;65:298-308. [PMID: 31646851 DOI: 10.23736/S1121-421X.19.02621-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
81 Fontanelli Sulekova L, Gabrielli S, Furzi F, Milardi GL, Biliotti E, De Angelis M, Iaiani G, Fimiani C, Maiorano M, Mattiucci S, Taliani G. Molecular characterization of Blastocystis subtypes in HIV-positive patients and evaluation of risk factors for colonization. BMC Infect Dis 2019;19:876. [PMID: 31640585 DOI: 10.1186/s12879-019-4537-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
82 Häger J, Bang H, Hagen M, Frech M, Träger P, Sokolova MV, Steffen U, Tascilar K, Sarter K, Schett G, Rech J, Zaiss MM. The Role of Dietary Fiber in Rheumatoid Arthritis Patients: A Feasibility Study. Nutrients 2019;11:E2392. [PMID: 31591345 DOI: 10.3390/nu11102392] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
83 Smith MK, Pai J, Panaccione R, Beck P, Ferraz JG, Jijon H. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol 2019;19:162. [PMID: 31488067 DOI: 10.1186/s12876-019-1067-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
84 Fluxa D, Abreu MT. Therapeutic targets in inflammatory bowel disease. Revista Médica Clínica Las Condes 2019;30:315-322. [DOI: 10.1016/j.rmclc.2019.06.008] [Reference Citation Analysis]
85 Gompertz M, Sedano R. Manifestaciones clínicas y endoscópicas en enfermedad inflamatoria intestinal. Revista Médica Clínica Las Condes 2019;30:273-282. [DOI: 10.1016/j.rmclc.2019.06.002] [Reference Citation Analysis]
86 Amara J, Saliba Y, Hajal J, Smayra V, Bakhos JJ, Sayegh R, Fares N. Circadian Rhythm Disruption Aggravates DSS-Induced Colitis in Mice with Fecal Calprotectin as a Marker of Colitis Severity. Dig Dis Sci 2019;64:3122-33. [PMID: 31115725 DOI: 10.1007/s10620-019-05675-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
87 Sedano Muñoz R, Quera Pino R, Ibáñez Lazo P, Figueroa Corona C, Flores Pérez L. Aminosalicilatos, tiopurínicos y metotrexato en la enfermedad inflamatoria intestinal, ¿es posible suspender el tratamiento? Gastroenterología y Hepatología 2019;42:339-347. [DOI: 10.1016/j.gastrohep.2019.01.013] [Reference Citation Analysis]
88 Sedano Muñoz R, Quera Pino R, Ibáñez Lazo P, Figueroa Corona C, Flores Pérez L. Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment? Gastroenterología y Hepatología (English Edition) 2019;42:339-347. [DOI: 10.1016/j.gastre.2019.01.016] [Reference Citation Analysis]
89 Bausch K, Roth E, Heinz S, Horst D, Mathia S, Vlajnic T, Bubendorf L, Westhoff T, Wetterauer C, Seifert HH, Ebbing J. Urinary Calprotectin loses specificity as tumour marker due to sterile leukocyturia associated with bladder cancer. PLoS One 2019;14:e0213549. [PMID: 30870488 DOI: 10.1371/journal.pone.0213549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
90 Tursi A, Elisei W. Role of Inflammation in the Pathogenesis of Diverticular Disease. Mediators Inflamm 2019;2019:8328490. [PMID: 31001067 DOI: 10.1155/2019/8328490] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
91 Picard E, Carvalho FA, Agosti F, Bourinet E, Ardid D, Eschalier A, Daulhac L, Mallet C. Inhibition of Cav 3.2 calcium channels: A new target for colonic hypersensitivity associated with low-grade inflammation. Br J Pharmacol 2019;176:950-63. [PMID: 30714145 DOI: 10.1111/bph.14608] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
92 Azramezani Kopi T, Shahrokh S, Mirzaei S, Asadzadeh Aghdaei H, Amini Kadijani A. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench 2019;12:183-9. [PMID: 31528300] [Reference Citation Analysis]
93 Quigley EMM. Editorial: From eosinophils to serrated adenomas and beyond: late breaking news from the dark continent. Curr Opin Gastroenterol 2019;35:25-6. [PMID: 30489413 DOI: 10.1097/MOG.0000000000000496] [Reference Citation Analysis]